PHARMACEUTICAL RESEARCH AND MANUFA… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1965

Legal Domicile

Phone

2025727756

Tax Period

2025-01-01 to 2025-12-31

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FDN INC, founded in 1965, is a community nonprofit that reported $4.9M in total revenue in fiscal year 2025. Revenue grew 14% year-over-year, indicating healthy expansion. Net assets of $27.3M represent 67 months of operating reserves.

Mission

THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE.

Program Service Accomplishments

Program 1

Expenses: $1,341,859 Revenue: $0

Drug Discovery - funds early career academic scientists who are pioneering new approaches to drug discovery. We support research projects that have the potential to make a significant impact for...

Drug Discovery - funds early career academic scientists who are pioneering new approaches to drug discovery. We support research projects that have the potential to make a significant impact for patients. By funding the drug discovery research of promising young scientists, the Foundation helps accelerate the identification of new therapeutic compounds and modalities while building a talent base to support innovation across the biopharmaceutical industry.

Program 2

Expenses: $1,055,367 Revenue: $0

Drug Delivery - Funds researchers studying ways to optimize drug composition, dosage, and delivery to make treatments safer, more effective, and easier to manage for patients.

Program 3

Expenses: $901,315 Revenue: $0

Value Assessment-Health Outcomes Research (VA-HOR) - supports early career researchers engaged in a multidisciplinary, collaborative research that investigates challenges and potential solutions...

Value Assessment-Health Outcomes Research (VA-HOR) - supports early career researchers engaged in a multidisciplinary, collaborative research that investigates challenges and potential solutions related to evaluating the delivery, safe use, effectiveness, and value (clinical, patient-centered, and economic) of medicines and other health care interventions.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $2,829,510

Program Service Revenue $0

Investment Income $2,073,089

Other Revenue $0

TOTAL REVENUE $4,902,599

Expense Breakdown

Grants Paid $3,708,833

Salaries & Benefits $1,144,793

Fundraising Expenses $3,234

Program Expenses $4,634,099

Other Expenses $347,603

TOTAL EXPENSES $5,201,229

Year-over-Year Comparison

	2025	2024	Change
Revenue	$4,902,599	$4,293,133	+0.1%
Expenses	$5,201,229	$4,981,861	+0.0%
Net Income	$-298,630	$-688,728	-0.6%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$613,926

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ANDREW PLUMP MD PHD	CHAIRMAN	1.0	Officer Director	$0	$0	$0
AIDA HABTEZION MD MSC FRCP	DIRECTOR (THRU 3/2025)	1.0	Director	$0	$0	$0
DANIEL SKOVRONSKY MD PhD	DIRECTOR	1.0	Director	$0	$0	$0
DONATELLO CROCETTA	Director	1.0	Director	$0	$0	$0
FIONA H MARSHALL PHD FMedSci FRS	DIRECTOR (AS OF 6/2025)	1.0	Director	$0	$0	$0
GEORGE ADDONA PHD	DIRECTOR	1.0	Director	$0	$0	$0
JOHN REED MD PhD	DIRECTOR	1.0	Director	$0	$0	$0
LORI REILLY Esq	EX OFFICIO MEMBER	1.0	Director	$0	$0	$0
PATRIZIA CAVAZZONI MD	DIRECTOR (AS OF 6/2025)	1.0	Director	$0	$0	$0
ROBERT PLENGE MD PHD	DIRECTOR	1.0	Director	$0	$0	$0
AMY MILLER	PRESIDENT	37.5	Officer	$535,515	$78,411	$613,926
EMILY ORTMAN	SENIOR DIRECTOR	37.5	Highest	$204,960	$64,962	$269,922
JOANNE WESTPHAL	DIRECTOR	37.5	Highest	$184,732	$37,717	$222,449

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$4,902,599	$5,201,229	$28,801,189	$-298,630
2024	$4,293,133	$4,981,861	$27,568,119	$-688,728
2024	$4,293,133	$4,981,861	$27,568,119	$-688,728
2023	$4,244,730	$4,366,003	$24,481,309	$-121,273
2022	$3,902,642	$4,077,991	$22,787,225	$-175,349
2021	$3,693,166	$4,358,423	$26,230,760	$-665,257
2020	$5,133,283	$4,843,015	$24,587,050	$290,268
2019	$4,815,154	$5,181,735	$23,711,048	$-366,581
2018	$5,190,784	$4,129,057	$21,895,305	$1,061,727

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FDN INC